Prevalence of Pericarditis and Myocarditis after mRNA COVID-19 Vaccine

There are several researchers worldwide reported several cases of pericarditis and myocarditis following the administration of COVID-19 mRNA vaccines. This study aimed to assess the prevalence of pericarditis or myocarditis after receiving the COVID-19   mRNA vaccine, to identify the most susceptible age group, and to find the most common risk factors. It is a non-interventional cross-sectional study that will be conducted for 12 months. Data were collected from the patient’s file and taking a direct history from the patient him/herself in the Makkah region. This study's success was possible due to ethical considerations observed by the researchers involved. To begin with, all the participants involved in the data collection process were informed of the study’s objective to allow them to participate in the exercise voluntarily.  A total of 10 patients who met the inclusion criteria were involved in the study. Among those involved, 70% 0f the population was female while the remaining 30% were male. The youngest patient in the sample population was 17 years whereas the oldest was 59 years of age. 70% of the respondents were diagnosed with pericarditis while 30% were diagnosed with myocarditis. Those who had received all the 3 doses were more likely to be affected by these health complications. A high number of the younger population were more likely to be diagnosed with either pericarditis or myocarditis events compared to older people. These health conditions often became prevalent 7 days after an individual has received the initial COVID-19 mRNA Vaccine.